Atlas Antibodies

13/01/2025

Learn more about resolving architecture with :

🔬https://ow.ly/SOSc50UFeyP 🔍

By identifying and characterizing cell type-specific markers, we can establish a baseline of what constitutes a healthy brain. From this knowledge we can detect deviations associated with various .

RESOLVING BRAIN ARCHITECTURE WITH SPATIAL PROTEOMICS

09/01/2025

🧠 Primary Antibodies Targeting Brain Proteome

Atlas Antibodies manufactures enhanced validated primary antibodies designed to map the brain proteome in both health and disease. Validated for multiple applications like IHC, ICC-IF, ChIP and WB, these antibodies ensure precise and reproducible results, supporting discoveries in neuroscience.

⏰ Limited-Time Offer: Enjoy 20% off on all brain-related primary antibodies!

👉🏼 Learn more and take advantage of this offer here: https://ow.ly/2csl50Uthol

08/01/2025

🎉 First Atlas Antibodies reference 2025:
👉🏼 Role of S100A Proteins in Glioblastoma Microenvironment

Recent research by Cómitre-Mariano et al. (Theranostics, 2025) highlights the distinct roles of S100A proteins in shaping the glioblastoma tumor microenvironment (TME).

The study utilized two Atlas Antibodies products in immunohistochemistry (IHC) and immunofluorescence (IF):

🔬 Anti-S100A13 (HPA019592): used to detect S100A13 in the tumor peripheries, this antibody revealed colocalization with microglial markers, such as P2RY12. S100A13 expression was elevated in tumors with higher microglial content and was co-expressed with microglial markers, supporting its role in microglial activation in GBM.

🔬 Anti-P2RY12 (HPA014518): employed to label microglial cells, this antibody confirmed the microglial localization of S100A13 in peripheral tumor regions. The findings highlight the association of S100A13 with neuroinflammation at the tumor’s invasive edge.

Read more about the study here: https://ow.ly/hISa50UBLgh

A recent study has elucidated the differential roles of S100A proteins in defining the Glioblastoma tumor microenvironment (TME). The study features two Atlas Antibodies’ products used in immunohistochemistry (IHC) and immunofluorescence (IF): the anti-S100A13 (Cat. HPA019592) and the Anti-P2RY12 ...

20/12/2024

🎄 Season's Greetings from Atlas Antibodies

As festivities are approaching, we at Atlas Antibodies want to extend our heartfelt gratitude to our incredible scientific community. Your dedication to advancing research inspires us every day, and we are proud to support your research and discoveries with our high-quality antibodies and tools for protein detection.

We wish you and your loved ones a joyous holiday season filled with warmth, peace, and happiness.
May the coming year bring new discoveries, collaborations, and success to your work.

Thank you for choosing Atlas Antibodies. We look forward to continuing this journey with you!

Happy Holidays
The Atlas Antibodies Team

17/12/2024

🔬 Atlas Antibodies is Live at Cell Bio 2024! 🔬

We’re thrilled to be exhibiting at booth #833 during Cell Bio 2024 in San Diego, CA. It’s been an exciting event, especially following our Tech Talk, where attendees explored the capabilities of our groundbreaking platform for in situ protein-protein interaction analysis!

A huge thank you to everyone who visited and showed great interest in MolBoolean.

📍 Stop by Booth #833 to learn how can support your research.

16/12/2024

Thank you to everyone who joined us at Atlas Antibodies' Tech Talk during Cell Bio 2024 in sunny San Diego!

It was a pleasure sharing insights into our revolutionary MolBoolean™ technology, designed to elevate your protein research to new heights.

👏 A special shoutout to our amazing speakers: Mikael Malmqvist, Nancy Dekki Shalaly, and Yuanhuang (Harry) Chen.

Missed the talk? Don’t worry - you can still explore how MolBoolean™ is transforming research workflows and delivering results that matter here: https://ow.ly/4Tfq50UrFAn

12/12/2024

Discovering the intricacies of drug targets is a vital step toward advancing precision medicine.

In a study published in Science Advances, Professor Thomas Sakmar from Rockefeller University used to investigate the interactions between 215 cell surface receptors, targets of one-third of all FDA-approved drugs, and their associated proteins.

WELCOME to join Atlas Antibodies Tech Talk at Cell Bio 2024 in San Diego, where Thomas Sakmar´s PhD student Yuanhuang (Harry) Chen will be a guest speaker. He will, together with our Product Manager Nancy Dekki Shalaly and Principal Scientist Mikael Malmqvist present our cutting-edge MolBoolean™ technology for in situ protein-protein interaction analysis.

Learn more about technology: https://ow.ly/miV850UpFMq

11/12/2024

🌟 Beyond Proximity Ligation: Discover MolBoolean™ at Cell Bio 2024!
https://www.atlasantibodies.com/products-g157/molboolean-kit-info/

😃 Join Atlas Antibodies' Tech Talk at Cell Bio 2024 in San Diego, where we’ll be presenting our cutting-edge MolBoolean™ technology for in situ protein-protein interaction analysis.

This next-gen technology provides spatial quantitative analysis of protein-protein interactions by the simultaneous detection of free and interacting proteins, data normalization and deeper insights into proteins dynamics.

Don’t miss it and learn how MolBoolean™ can transform your research.

🌎 ASCB/EMBO Cell Bio Conference 2024
📅 Tech Talk: Sunday, Dec 15, 1:15 PM - 2:00 PM�
📍 Location: Meeting Room 21�

09/12/2024

🔬 ENHANCED VALIDATED ANTIBODIES FOR TISSUE AND CELL ANALYSIS
Unmatched Reliability in Proteomics Research

Take advantage of a 20% discount on over 300 premium primary antibodies, specifically designed for targeting brain cell types.

Atlas Antibodies provide the accuracy you need to advance your research with confidence.
Don’t miss this opportunity to elevate your work with top-tier antibodies at a great price!

👉🏼 Unlock discounted prices at checkout!
https://www.atlasantibodies.com/knowledge-hub/product-news/primary-antibodies-for-mapping-the-brain-proteome-in-health-and-disease/

Take advantage of a 20% discount on over 300 premium primary antibodies, specifically designed for targeting brain cell types. Our antibodies provide the accuracy you need to advance your research with confidence.